Expression of nuclear factor-kappa B and inducible nitric oxide synthase in peripheral blood mononucleated cells and immune status in patients with different stages of chronic hepatitis B

Huang Jin; Zhang MeiQuan; He DaoXing

doi:10.3969/j.issn.1001-5256.2020.03.013

Volume 36 Issue 3

Mar. 2020

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2020 > 36(3): 536-540

PDF( 2026 KB)

Expression of nuclear factor-kappa B and inducible nitric oxide synthase in peripheral blood mononucleated cells and immune status in patients with different stages of chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2020.03.013

Department of Infectious Diseases, Nanping First Hospital Affiliated to Fujian Medical University

Research funding:

Published Date: 2020-03-20

Abstract

Abstract

Objective To investigate the expression of nuclear factor-kappa B( NF-κB) and inducible nitric oxide synthase( iNOS) in peripheral blood mononucleated cells( PBMCs) of patients with different stages of chronic hepatitis B( CHB),as well as the changes in natural killer( NK),T,and B lymphocytes in each stage. Methods A total of 80 patients with CHB-related diseases who were admitted to Nanping First Hospital Affiliated to Fujian Medical University from October 2017 to January 2019 were enrolled and divided into four groups according to disease stage: hepatitis group,liver failure group,liver cirrhosis group,and liver cancer group,with 20 patients in each group,and ten healthy volunteers were enrolled as control group. Flow cytometry was used to measure total lymphocyte count as well as the counts of lymphocyte subsets in peripheral blood in all five groups,Western blot was used to measure the protein expression of NF-κB and iNOS in PBMCs,and the nitrate reductase method and ELISA were used to measure the serum levels of nitric oxide( NO) and interleukin-6( IL-6). A one-way analysis of variance was used for comparison between multiple groups,and the least significant difference t-test was used for further comparison between two groups. Results Compared with the control group,the hepatitis group,the liver failure group,the liver cancer group,and the liver cirrhosis group had a significant reduction in total lymphocyte count( all P < 0. 05),and compared with the hepatitis group,the liver failure group,the liver cancer group,and the liver cirrhosis group had a significant reduction in total lymphocyte count( all P < 0. 05). The liver failure group,the liver cancer group,and the liver cirrhosis group had a significant reduction in CD3+T cells compared with the control group and the hepatitis group( all P < 0. 05),as well as a significant reduction in CD4+T cells compared with the hepatitis group( all P < 0. 05); the liver failure group had a significant increase in CD8+T cells compared with the liver cancer group,the liver cirrhosis group,and the control group( all P < 0. 05); the liver failure group had a significant reduction in CD4+/CD8+compared with the control group,the hepatitis group,the liver cirrhosis group,and the liver cancer group( all P < 0. 05); the liver failure group and the liver cirrhosis group had a significant increase in CD3-CD19+B cells compared with the hepatitis group and the control group( all P < 0.05); the liver failure group and the liver cancer group had a significant reduction in CD16+CD56+NK cells compared with the hepatitis group and the control group( all P < 0. 05). The liver cirrhosis group,the liver failure group,and the liver cancer group had significant increases in the protein expression of NF-κB and iNOS compared with the hepatitis group and the control group( all P < 0. 05). Compared with the control group,the liver failure group,the liver cancer group,the liver cirrhosis group,and the hepatitis group had significant increases in the serum levels of NO and IL-6( all P < 0. 05). Conclusion There are certain differences in immune status between patients with different stages of HBV infection,and NF-κB-iNOS-NO may be involved in the immune response of HBV-related diseases.
- hepatitis B,chronic,
- NF-kappa B,
- nitric oxide synthase,
- lymphocytes

FullText(HTML)

References(16)

References

[1] PAN CJ,WU HL,KUO SF,et al. Serum interleukin 6 level correlates with outcomes of acute exacerbation of chronic hepatitis B[J]. Hepatol Int,2012,6(3):591-597.

[2] HONG M,BERTOLETTI A. Tolerance and immunity to pathogens in early life:Insights from HBV infection[J]. Semin Immunopathol,2017,39(6):643-652.

[3] DU Z,DONG J,BI J,et al. Correction:Predictive value of the preoperative neutrophil-to-lymphocyte ratio for the development of hepatocellular carcinoma in HBV-associated cirrhotic patients after splenectomy[J]. PLo S One,2019,14(4):e0215183.

[4] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J]. J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会，中华医学会感染病学分会．慢性乙型肝炎防治指南(2015年更新版)[J]．临床肝胆病杂志，2015,31(12):1941-1960.

[5] Liver Failure and Artificial Liver Group,Chinese Society of Infectious Diseases,Chinese Medical Association; Severe Liver Disease and Artificial Liver Group,Chinese Society of Hepatology,Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol,2019,35(1):38-44.(in Chinese)中华医学会感染病学分会肝衰竭与人工肝学组，中华医学会肝病学分会重型肝病与人工肝学组．肝衰竭诊治指南(2018年版)[J]．临床肝胆病杂志，2019,35(1):38-44.

[6] SHI HM,LI R,CHEN H,et al. An excerpt of EASL clinical practice guidelines for the management of patients with decompensated cirrhosis(2018)[J]. J Clin Hepatol,2018,34(8):1632-1638.(in Chinese)史慧敏，李瑞，陈红，等．《2018年欧洲肝病学会失代偿期肝硬化患者的管理临床实践指南》摘译[J]．临床肝胆病杂志，2018,34(8):1632-1638.

[7] National Health and Family Planning Commission of the People's Republic of China. Diagnosis,management,and treatment of hepatocellular carcinoma(V2017)[J]. J Clin Hepatol,2017,33(8):1419-1431.(in Chinese)中华人民共和国国家卫生和计划生育委员会．原发性肝癌诊疗规范(2017年版)[J]．临床肝胆病杂志，2017,33(8):1419-1431.

[8] WANG Y,CHEN C,QI J,et al. Altered PGE2-EP2 is associated with an excessive immune response in HBV-related acute-on-chronic liver failure[J]. J Transl Med,2019,17(1):93.

[9] ZHANG W,ZHANG J,ZHAO L,et al. TIPE2 protein negatively regulates HBV-specific CD8+T lymphocyte functions in humans[J]. Mol Immunol,2015,64(1):204-209.

[10] GAO W,KONG M,YAO J,et al. Changes in prealbumin and body mass index associated with T lymphocyte subsets and nutritional status in chronic hepatitis B and HBV-cirrhosis patients[J]. Clin Lab,2018,64(11):180-184.

[11] SUN KK,HUANG CH,WANG YY,et al. Detection of T lymphocyte surface costimulatory molecules and T lym-phocyte subsets in peripheral blood of HBV infected patients and its clinical significance[J]. Chin J Clin Pharmacol Ther,2019,24(3):241-247.(in Chinese)孙凯凯，黄春红，王云云，等．HBV感染者外周血T淋巴细胞表面共刺激分子和T淋巴细胞亚群的检测及临床意义[J]．中国临床药理学与治疗学，2019,24(3):241-247.

[12] BAARDY F,MALMASSARI S,DENG Q,et al. Hepatitis B virus(HBV)-derived DRB1*0101-restricted CD4 T-cell epitopes help in the development of HBV-specific CD8+T cells in vivo[J]. Vaccine,2010,28(22):3818-3826.

[13] QI X,GUI X,ZHUANG K,et al. Establishment and characterization of HBV-associated B lymphocytes with an immortalization potential[J]. PLo S One,2019,14(5):e0217161.

[14] LIN J,GU C,SHEN Z,et al. Hepatocyte nuclear factor 1αdownregulates HBV gene expression and replication by activating the NF-κB signaling pathway[J]. PLo S One,2017,12(3):e0174017.

[15] SASAKI Y,IWAI K. Roles of the NF-κB pathway in B-lymphocyte biology[J]. Curr Top Microbiol Immunol,2016,393:177-209.

[16] MA XL,LI YH,GAO JX,et al. Effect and its'significance of NF-κB on inducible nitric oxide expression in concanavalin A induced immune liver injury[J]. J Shandong Univ(Health Sciences),2005,43(2):98-102.(in Chinese)马雪莲，李跃华，高建新，等．刀豆蛋白A诱导的肝损伤中核因子-κB对诱导型一氧化氮合酶表达的调控及其意义[J]．山东大学学报(医学版)，2005,43(2):98-102.

Relative Articles

[1]	Yunchong WU, Yanyan YANG, Chuan LI, Xiaohuan WU, Shide LIN. Role of inflammatory cytokines in disorder of glucose metabolism in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2024, 40(9): 1886-1890. doi: 10.12449/JCH240926
[2]	Zhan ZENG, Yuanjiao GAO, Xiaoyue BI, Fengxin CHEN, Wen DENG, Tingting JIANG, Yanjie LIN, Liu YANG, Minghui LI, Yao XIE. Value of HBsAg level in predicting liver inflammation in patients with HBeAg-positive chronic hepatitis B virus infection and normal alanine aminotransferase[J]. Journal of Clinical Hepatology, 2022, 38(5): 1030-1034. doi: 10.3969/j.issn.1001-5256.2022.05.011
[3]	Huaqian XU, Xue LI, Shanhong TANG. Research advances in the role of inflammatory response and related treatment strategies in acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(8): 1927-1930. doi: 10.3969/j.issn.1001-5256.2022.08.041
[4]	Ting LI, Huabao LIU, Wenyan HU, Chunyan RAO. Role of inflammation in hepatic fibrosis[J]. Journal of Clinical Hepatology, 2022, 38(10): 2368-2372. doi: 10.3969/j.issn.1001-5256.2022.10.032
[5]	Xinlan ZHOU, Xin MA, Yanbing WANG, Xiufen LI, Dan HUANG, Wei LU, Zhanqing ZHANG, Rongrong DING. Value of aspartate aminotransferase-to-platelet ratio index, fibrosis-4, and gamma-glutamyl transpeptidase-to-platelet ratio in diagnosis of liver inflammation grade in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2021, 37(9): 2066-2070. doi: 10.3969/j.issn.1001-5256.2021.09.013
[6]	Yao LI, Jingchao WANG, Jiaqi YUAN, Hao WEN, Ying ZHOU, Haining FAN, Zhixin WANG. Influence of endoplasmic reticulum stress on the secretion of some inflammatory mediators in hepatic alveolar echinococcosis[J]. Journal of Clinical Hepatology, 2021, 37(1): 131-134. doi: 10.3969/j.issn.1001-5256.2021.01.026
[7]	Wang TingShuai, Wang Na, Zhang RongZhen, Wang MingGang, Huang ShaoDong, Ma YuZhen, Wu Cong, Mao DeWen. Role of immune response and inflammatory injury in the pathogenesis of liver failure[J]. Journal of Clinical Hepatology, 2020, 36(6): 1415-1419. doi: 10.3969/j.issn.1001-5256.2020.06.050
[8]	Yin JinPing, Yue ZiChen, Zhuo ShaoYuan. STAT3: A key molecule in the progression of liver cancer mediated by chronic inflammation[J]. Journal of Clinical Hepatology, 2020, 36(4): 948-952. doi: 10.3969/j.issn.1001-5256.2020.04.054
[9]	Guo Yan, Huang Li, Yang GuoChao, Liu Shan, Du LinNa, Wang MinJuan. Association between nonalcoholic fatty liver disease and dietary inflammation index and its practical significance[J]. Journal of Clinical Hepatology, 2019, 35(10): 2324-2326. doi: 10.3969/j.issn.1001-5256.2019.10.042
[10]	Liu Li, Li JunYi, Du YingRong, Huang HongLi, Luo Yu, Li HuiMin, Li WeiKun, Wang Lin, Liu ChunYun. Influencing factors for liver inflammation grade and fibrosis degree in patients with low-level HBV DNA[J]. Journal of Clinical Hepatology, 2019, 35(5): 982-986. doi: 10.3969/j.issn.1001-5256.2019.05.010
[11]	He Yang, Su YaRong, Han ZiYan. Current status of research on primary and secondary risk factors for esophagogastric variceal rebleeding in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2018, 34(7): 1555-1559. doi: 10.3969/j.issn.1001-5256.2018.07.041
[12]	Wang WanQin, Wen MaoYao, Fan XiaoLi, Shen Yi, Yang XiaoXue, Yang Li. Research advances in liver cirrhosis complicated by portal vein thrombosis[J]. Journal of Clinical Hepatology, 2016, 32(7): 1409-1412. doi: 10.3969/j.issn.1001-5256.2016.07.045
[13]	Zhang XinTong, Qi XingShun, Gao Fan, Guo XiaoZhong. Research advances in venous thromboembolism in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(10): 2004-2006. doi: 10.3969/j.issn.1001-5256.2016.10.043
[14]	Li Qiang, Huang YuXian, Chen Liang. Simple serum markers for significant liver inflammation in chronic hepatitis B patients with an alanine aminotransferase level lower than 2 times upper limit of normal[J]. Journal of Clinical Hepatology, 2016, 32(6): 1125-1129. doi: 10.3969/j.issn.1001-5256.2016.06.021
[15]	Ding Jie, Wang Liang, Li Juan, Kong Yin, Zhao Rui, He JingJing, Li GuangMing, Wang JuanXia, Zhang LingYi. Changes in serum asymmetric dimethylarginine levels in progression of liver inflammation in an experimental rat model of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2016, 32(1): 148-151. doi: 10.3969/j.issn.1001-5256.2016.01.029
[16]	Zhu JuanJuan, Cheng MingLiang, Zhao XueKe. Role of liver immunological inflammation in development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2016, 32(3): 570-573. doi: 10.3969/j.issn.1001-5256.2016.03.038
[17]	Wu YuJing, Guo JinSheng. Hepatic stellate cells,Toll-like receptor 4 signaling pathway,and inflammatory fibrotic microenvironment in the development of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2015, 31(6): 876-879. doi: 10.3969/j.issn.1001-5256.2015.06.012
[18]	Wang JingYun, Sun Jing, Gao YanHang. Research advances in liver cirrhosis complicated by bacteremia[J]. Journal of Clinical Hepatology, 2014, 30(7): 683-686. doi: 10.3969/j.issn.1001-5256.2014.07.030
[19]	Dong HongYun, Zhao GuiMing, Li Ying. Study on the relationship between inflammation activity in the liver tissues and expression of HBcAg in patients with chronic hepatits B[J]. Journal of Clinical Hepatology, 2007, 23(1): 13-14.

Supplements(0)

Cited By

Cited by

Periodical cited type(2)

1.	魏文敏. 血脂指标与血清转氨酶、胆碱酯酶、γ-谷氨酰转肽酶联合检验在非酒精性脂肪肝病诊断中的应用. 中外医学研究. 2024(20): 78-81 .
2.	胡丽军，连倩倩. 超声声衰减成像定量参数联合RC/HDL-C诊断MAFLD肝脂肪变程度的效能及与脂代谢的相关性. 肝脏. 2024(10): 1260-1264 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1143) PDF downloads(234)

Expression of nuclear factor-kappa B and inducible nitric oxide synthase in peripheral blood mononucleated cells and immune status in patients with different stages of chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2020.03.013